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 Sorafenib is the only chemotherapeutic approved for treatment of advanced 
hepatocellular carcinoma (HCC.) However, its effectiveness in patients with Child Pugh B 
cirrhosis and any moderating effects of health system characteristics are unclear. We aimed to 
examine the survival and cost-effectiveness associated with sorafenib in elderly patients with 
advanced HCC. We performed an analysis of Medicare beneficiaries with HCC diagnoses from 
2007-2009. We compared advanced stage patients with HCC (AJCC stage III/IV) who received 
sorafenib within 6 months of diagnosis (and were otherwise untreated) to advanced stage 
patients with HCC who received no therapy (control.) We performed univariate and multivariate 
analyses to identify predictors of survival. Incremental cost effectiveness ratios (ICERs) were 
calculated for sorafenib-treated and control patients. We included 228 sorafenib-treated patients 
and 870 control patients. The median survival of the sorafenib-treated patients was 150.5 days 
versus 62 days for control patients. In multivariate analysis, significant predictors of improved 
survival were treatment with sorafenib (HR: 0.66; 95% CI: 0.57-0.77), being seen at a National 
Cancer Institute-designated cancer center (HR: 0.77; 95%CI: 0.62-0.97) or transplant center 
(HR: 0.77; 95% CI: 0.65-0.93.) Predictors of worse survival included Stage IV disease (HR: 
1.40; 95%CI: 1.24-1.58), decompensated cirrhosis (HR: HR: 1.49; 95%CI: 1.30-1.70,) and 
treatment in an urban setting (HR: 1.45; 95% CI: 1.21-1.73.) Although sorafenib use was 
associated with a survival benefit (0.61, 95% CI: 0.47-0.79) among patients with 
decompensated cirrhosis, the median survival benefit was 31 days and it was not cost-effective 
with an ICER of $224,914 per life year gained. Conclusions: Sorafenib is associated with 
improved survival in elderly patients with advanced HCC; however it is not cost-effective among 
those with hepatic decompensation. 
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 Hepatocellular carcinoma (HCC) is an increasingly incident and morbid malignancy.(1) 
Patient tumor burden, functional status, and underlying liver function are recognized predictors 
of patient mortality with HCC.(2) Unfortunately, many patients present with advanced HCC and 
can only be treated with palliative therapies, which are designed to extend life but are not 
capable of achieving cure. Sorafenib, a multikinase inhibitor, is the only approved systemic 
therapy for patients with unresectable or metastatic disease.(3) In the SHARP trial, a 
randomized control trial among Child-Pugh class A patients with a Eastern Cooperative 
Oncology Group (ECOG) status of 0-1 and advanced HCC, sorafenib increased survival by 
approximately 3 months compared to placebo.(4) The American Association for the Study of 
Liver Disease (AASLD) and European Association for the Study of the Liver (EASL) guidelines 
recommend sorafenib as the first-line therapy for Barcelona Clinic Liver Cancer (BCLC) stage C 
patients, i.e. those with unresectable HCC, ECOG status of 1-2, and Child-Pugh class A or B 
liver function.  
However, the benefit of sorafenib in patients with advanced liver disease (i.e. Child-Pugh 
class B), particularly those with ascites or hepatic encephalopathy, is unclear given limited 
available data.(3) The Global Investigation of Therapeutic Decision In Hepatocellular Carcinoma 
and if its Treatment with Sorafenib (GIDEON) data suggest sorafenib is well tolerated by 
patients with Childs-Pugh class B cirrhosis and advanced HCC with a median survival of 5.2 
months, but this post-marketing study did not have a comparator arm so analyses of survival 
benefit have relied on comparisons to historical controls.(5, 6) Further, we lack an 
understanding of how health system characteristics, e.g. being seen at a tertiary care referral 
center, impact treatment effectiveness and survival. The population of patients with HCC is 
shifting to a more elderly demographic, largely due to an aging population with chronic hepatitis 
C virus (HCV) infection; thus, the impact of age and accumulated comorbidities is becoming 
increasingly relevant when making HCC treatment decisions.(7)  
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To address the gaps in the existing literature, we aimed to analyze the Surveillance 
Epidemiology and End Results (SEER) Medicare linked database to determine the survival 




 We performed a secondary analysis of the SEER-Medicare data linked dataset with Part 
D data for new diagnoses of HCC from 2007-2009. The details of SEER-Medicare data are 
described elsewhere.(8) Part D is a United States federal program instituted in 2006 that 
subsidized medications for Medicare beneficiaries. The Part D data included in SEER-Medicare 
includes medications prescribed, number of prescriptions filled, and medication costs.(9)  
 
Patient Selection 
 We included Medicare patients with continuous enrollment in Medicare Parts A & B from 
12 months prior to diagnosis through the end of follow-up (December 31, 2010), allowing up to a 
3-month gap in coverage per year. We included SEER-Medicare patients with a diagnosis of 
HCC (International Classification of Diseases for Oncology, Third Edition, histology codes 8170 
through 8175 and 8180 for HCC and site code C22.0 for liver.)(10)  Patients with another 
malignant primary tumor diagnosed prior to HCC diagnosis and patients who had HCC 
diagnosed upon death were excluded. We included American Joint Committee on Cancer 
(AJCC) Stage III and IV HCC based on the SEER staging guide to identify patients with 
advanced HCC. Patients with missing data on tumor stage were excluded.  Those with dates of 
birth that differed between Medicare and SEER by more than a year were removed from the 
analysis, as were any patients with autopsy or death certificate-only records. We compared 
patients who received only sorafenib therapy through the Part D program to patients who 
received no therapy (control group) during the study period. To identify control patients, we 
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excluded patients who had any ICD-9 codes for surgical resection, liver transplantation, liver 
directed therapies (ablative procedures, radiation therapy, transarterial chemoembolization, 
transarterial radioembolization,) and other systemic therapies. Patients were followed from HCC 
diagnosis to death or end of follow-up. 
 
Covariates 
 Covariates of interest included patient-level factors (age, gender, race, comorbidities, 
and presence of hepatic decompensation,) and system-level factors, (region of country, 
residence in an urban vs. rural area [as defined by residence in a metropolitan statistical area,] 
association with liver transplant center, and National Cancer Institute (NCI)-designation.) We 
calculated Charlson comorbidity index using data from 12 months prior to HCC diagnosis, 
excluding codes for liver disease, as previously described.(11) We excluded liver disease codes 
from the comorbidity index as nearly all patients had underlying chronic liver disease, if not 
cirrhosis (12); further, we were interested in exploring the prognostic significance of hepatic 
decompensation independent of other comorbidities. We developed a composite variable for 
liver decompensation that included administrative codes for: 1) ascites (ICD-9 789.5x) and 
procedural coding for paracentesis (HCPCS 49080 - 49084); 2) hepatic encephalopathy (ICD-9 
572.2, 070.4x, 070.6x) and medication codes from Part D for neomycin, lactulose and rifaximin; 
or 3) esophageal varices (ICD-9 456.0, 456.1, 456.2) and procedural coding for 
esophagogastroduodenoscopy (EGD) with variceal banding (HCPCS 43205, 43244, 43251, 
43999, 46934). We performed a sensitivity analysis excluding esophageal varices from the 
definition of decompensation, as its inclusion without overt variceal bleeding is controversial. 
 
ECOG Sensitivity Analysis 
 ECOG score is an important prognostic marker in patients with advanced HCC, both for 
staging and prognosis, however it is not captured in the SEER-Medicare dataset. Therefore we 
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performed a sensitivity analysis to account for potential unmeasured confounding from 
ECOG.(13)  Based on previously published data, our sensitivity analysis examined the hazard 
ratios associated with ECOG 3-4 status of 1.5 and 2.0 and its impact on sorafenib associated 
survival benefit in the multivariate model.(14) We varied the proportion with high ECOG status in 
the treatment group from 0-50% in increments of 10% and from 0-100% in increments of 10% in 
the control group. 
 
Cost Analysis 
 Total costs from the Medicare perspective were compiled using Medicare Part A, B, and 
D data files from diagnosis to the end of follow-up. We compared costs for sorafenib-treated 
patient and control patients and calculated incremental cost-effectiveness ratios (ICERs) per life 
year gained. ICER is defined as the difference in costs divided by year of life gained, and 
compared to the accepted threshold of $100,000 per life-year for cost-effective treatments.(15-
18) We used life-year gained instead of quality life-year gained, as there are no available 
validated quality of life utility adjustments for patients on sorafenib therapy. All costs were 
inflated to 2015 US dollars. We performed a stratified analysis based upon the presence of liver 
decompensation, as defined above. 
 To examine the cost effectiveness ratio, we used a sensitivity analysis where our 
empirical distribution was resampled using replacement, giving us a total of 500 bootstrap 
permutations of the data.  We modeled the ICER statistic value for each of the 500 sets of data 
and checked its cumulative density function, producing a cost-effectiveness acceptability 
curve.(19, 20)  To assess the variation of the sample we considered the 2.5% and 97.5% 
nonparametric percentiles along with the median value. We also conducted traditional one-way 
sensitivity analyses by varying survival of the sorafenib treated group by 10% and 40% to test 
the robustness of our ICER estimates. 
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 Patient characteristics were compared between treated and control patients. Fisher 
exact and Kuskal Wallis tests were used for categorical and continuous variables, respectively, 
except age, which was symmetrically distributed and was evaluated with Student’s t test. The 
variables with distributions that deviated from normality were reported by median and 
interquartile range (Q1, Q3) and those with normal distribution were reported as mean ± 
standard deviation (SD). 
 We conducted Kaplan-Meier survival analysis with log rank tests to compare survival 
from the time of HCC diagnosis between strata. Propensity score adjustment was used to 
balance the cohorts using 1:1 nearest neighbor matching, accounting for the differences 
between the sorafenib-treated and untreated cohorts in our univariate analysis. The propensity 
score algorithm selected the other predictor variables by predicting the treatment variable in a 
logistic regression.  From that a predicted outcome comprised of a combination of the predictor 
variables with the slopes creates a propensity score, and this was used to match the treatment 
group subjects to the best control group subjects and discard the remainder.  We also 
performed propensity score matching for the subset of patients with decompensated cirrhosis. 
We constructed a multivariate Cox model to identify predictors of survival. The primary 
independent variable of interest was sorafenib treatment, with other covariates described above. 
We used variance inflation factors to test for collinearity in the model variables with the intention 
of sequentially removing variables where significant collinearity was present.  However no 
collinearity was found in any of our multivariate analyses, as all VIF values were less than 2.5. 
We also tested for any interaction between relevant variables (i.e. sorafenib treatment and 
decompensation) to determine if a stratified analysis was warranted, however no significant 
interactions were seen. We performed a sensitivity analysis to account for immortal time bias by 
conducting a time-dependent covariate survival analysis for sorafenib use.  All analyses were 
conducted in SAS 9.4 (SAS Institute, Cary NC) and R version 3.2.2. The R package “MatchIt” 
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was used for the propensity scores, the package “survival” was used for Cox Proportional 
Hazards regression, the package “RItools” was used for evaluation of propensity scores balance 
and “rms” was used to create the Kaplan Meier survival curves.(21-27) 
 
RESULTS 
 From 2007-2009, 8,102 patients with a new diagnosis of HCC were identified in the 
SEER-Medicare data set. A total of 5,125 patients had AJCC stage III or IV disease and of 




 A total of 228 patients were included in the sorafenib treated group and 870 patients 
were included in the untreated group. The characteristics of the two groups are shown in Table 
1. Patients in the untreated group were significantly older and more likely to be White or Black 
than sorafenib-treated patients. There were no significant differences in gender distribution or 
representation in regional areas of the United States.  The two groups had similar AJCC cancer 
stage at diagnosis and prevalence of decompensated cirrhosis, although the untreated group 
had a greater proportion of patients with a Charlson comorbidity index greater than 3. There 
were no differences between the groups regarding being seen at a NCI-designated cancer 
center or transplant center, but patients in the untreated group were significantly less likely to be 
seen at a teaching hospital.  
 
Survival 
Median survival of the entire cohort was 90 (IQR: 31-184) days, with 3-month, 6-month, 
and 1-year survival rates of 49.0%, 28.0%, and 12.0%, respectively. For sorafenib treated 
patients, mean time from HCC diagnosis to sorafenib initiation was 32.6 (±40.4) days. 
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Sorafenib-treatment was associated with a significantly better overall survival than untreated 
patients (p<0.001, Figure 1a). Median survival for patients treated with sorafenib from time of 
HCC diagnosis was 150.5 (IQR=62-273) days, while the median survival of the control groups 
was 62 (IQR=31-153) days. The 3-month, 6-month, and 1-year actuarial survivals for the 
sorafenib group and untreated group were 67.5%, 41.7%, and 18.0% vs. 44.1%, 24.4%, and 
10.5%, respectively.  
Multivariate analysis of the entire cohort showed there was a lower risk of mortality for 
sorafenib-treated patients (HR 0.66, 95%CI 0.57-0.77,) patients seen at a NCI-designated 
center (HR 0.77, 95%CI 0.62-0.97,) or at a transplant center (HR 0.77, 95%CI 0.62-0.97.)  
Independent predictors of higher mortality included stage IV tumor burden (vs. stage III) (HR 
1.40, 95%CI 1.24-1.58,) urban setting (HR 1.45, 95%CI 1.21-1.73,) and presence of hepatic 
decompensation (HR 1.49, 95%CI 1.30-1.70.) (Table 2) In a sensitivity analysis, removal of 
esophageal varices from the decompensation variable resulted in a similar hazard ratio in the 
multivariate model (HR: 1.43, 95% CI 1.29-1.59.) In another sensitivity analysis to account for 
immortal time bias, we considered sorafenib use as a time dependent variable, and we found 
that its use was associated with improved survival, however this failed to reach statistical 
significance (HR: 0.87, 95% CI: 0.74-1.01.) 
 
Stratification by Decompensation 
Sorafenib-treatment in patients with compensated liver disease (i.e. absence of ascites, 
hepatic encephalopathy or esophageal varices) was associated with a significantly better 
survival than untreated patients with compensated liver disease (p=0.002). The median survival 
of sorafenib-treated patients was 153 days (IQR=90-275.8) vs. 90.5 days (IQR=31-212) for 
untreated patients. Actuarial 3-month, 6-month and 1-year survival rates were 71.8%, 45.8%, 
and 19.7% vs. 50.0%, 28.8%, and 13.6%, respectively. 
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Sorafenib-treatment in patients with evidence of hepatic decompensation also was 
associated with a significantly better survival than untreated patients with decompensated liver 
disease (p < 0.001, Figure 1b). Although the relative benefit associated with sorafenib was 
similar to those with compensated liver disease, the absolute benefit associated with sorafenib 
in patients with hepatic decompensation was smaller. Median survival of the sorafenib-treated 
patients with hepatic decompensation was 92 days (IQR=61-205) vs. 61 days (IQR=31-122) for 
untreated patients. Actuarial 3-month, 6-month, and 1-year survival rates in sorafenib-treated 
and untreated patients were 60.5%, 34.9%, and 15.1% vs. 35.7%, 18.0%, and 5.9%, 
respectively. For patients with only one decompensation coded (n=59 for treatment and n=222 
for control,) the 3-month, 6-month, and 1-year survival rates were 57.6%, 39.0%, and 20.3% vs. 
36.9%, 18.9%, and 6.3%, respectively (p<0.001.) 
Table 3 shows the multivariate analysis of factors associated with survival in patients 
with hepatic decompensation (n=422).  Treatment with sorafenib (HR: 0.61, 95% CI: 0.47-0.79) 
and being seen at an NCI designated center (HR: 0.62, 95% CI: 0.45-0.86) were both 
associated with improved survival, while stage IV (vs stage III) disease (HR: 1.27, 95% CI 1.04-
1.56) and treatment in an urban setting (HR: 1.57, 95% CI: 1.14-2.16) were associated with 
increased mortality. 
 
Propensity Score Adjusted Analysis 
After matching sorafenib-treated to untreated patients with propensity scores, we 
balanced all available covariates individually and globally, removing baseline differences 
between the groups (Hansen-Bowers Chi-square 4.0, p=1.000.)  After discarding the 
unmatched population, there were 228 sorafenib-treated patients and 228 untreated patients 
remaining. Patient survival is shown in Figure 1c, with significantly better survival among 
sorafenib-treated patients than untreated patients (p<0.001). Median survival was 150.5 
(IQR=62-273) days in the sorafenib-treated group and 62 (IQR=31-213) days in the control 
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group. The 3-month, 6-month, and 1-year actuarial survival for the sorafenib treated group and 
untreated group were 67.5%, 41.7%, and 18.0% vs. 49.6%, 28.5%, and 11.0%, respectively.  In 
multivariate propensity score-adjusted analysis, sorafenib treated patients had a significantly 
lower risk of mortality (HR 0.55, 95%CI 0.46-0.67.) Factors significantly associated with higher 
risk of mortality in multivariate analysis included stage IV tumor burden (vs stage III) at 
diagnosis (HR 1.33, 95%CI 1.10-1.61), presence of hepatic decompensation (HR: 1.74, 95%CI 
1.40-2.16) and being treated at an urban center (HR 1.94, 95%CI 1.40-2.68); (Table 2.)  
We also performed propensity score matching of only the decompensated patients and 
included 81 patients in the sorafenib treated group and 81 patients in the untreated group. 
Patient survival was again better in the sorafenib treated patients (p=0.004.) The median 
survival was 92 (IQR=61-185) days in the sorafenib-treated group and 61 (IQR=31-122) days in 
the control group. The 3-month, 6-month, and 1-year actuarial survival for the sorafenib treated 
group and untreated group were 58.0%, 34.6%, and 16.1% vs 34.6%, 18.5%, and 4.9%, 
respectively. In the multivariate propensity score-adjusted analysis, sorafenib treated patients 
had a significantly lower risk of mortality (HR: 0.62, 95% CI: 0.45-0.87) as did patients who were 
seen at a transplant center (HR: 0.59, 95% CI: 0.38-0.92); (Supplemental Table 1.) Stage IV (vs 
Stage III) disease was the only factor associated with worse survival (HR: 1.48, 95% CI: 1.05-
2.08.) 
 
Predictors of Survival Among Sorafenib-Treated Patients 
Predictors of survival among sorafenib-treated patients on univariate analysis were 
treatment in an urban setting (HR 1.61, 95% CI 1.20-2.17 p=0.002), age (HR 0.98, 95% CI 0.97-
1.00, p=0.028), and presence of hepatic decompensation (HR 1.40, 95% CI 1.06-1.84, 
p=0.019.) Median survival of sorafenib-treated patients with and without hepatic 
decompensation was 92 and 153 days, respectively (Figure 2a; p=0.02). Similarly, overall 
survival among sorafenib-treated patients was significantly associated with the number of 
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unique hepatic decompensation codes for each patient (p=0.008, Figure 2b). Independent 
predictors of survival among sorafenib-treated patients in a multivariate analysis are shown in 
Supplemental Table 2. Being treated in an urban setting was the only significant predictor of 
mortality (HR: 2.12; 95% CI: 1.32-3.41). Hepatic decompensation was associated with 
increased risk of mortality (HR: 1.29 95% CI 0.94-1.76), but this difference did not reach 
statistical significance on multivariate analysis. 
 
ECOG Sensitivity Analysis 
 The results of the ECOG score sensitivity analysis are shown in Table 4. In the case 
where the ECOG 3-4 score associated HR was assumed to be 1.5, sorafenib was no longer 
associated with improved survival when the prevalence of ECOG 3-4 was greater than 40% for 
the control group and 0% for the sorafenib-treated patients. If there are any sorafenib-treated 
patients in the ECOG 3-4 group, the survival benefit associated with persists with even higher 
rates of ECOG 3-4 status in the control group.  
 In the case of an assumed HR of 2.0 associated with ECOG 3-4 status, sorafenib is 
associated with a survival benefit when the prevalence of ECOG 3-4 is lower than 20% in the 
control group. This threshold again increases with increasing prevalence of ECOG 3-4 in the 
sorafenib treated group. Once the prevalence of ECOG 3-4 becomes very high in the control 
group (>60%,) however, sorafenib is associated with worse survival when compared to controls. 
(Supplemental Table 3.)   
 
Costs 
 We analyzed cost differences between sorafenib-treated and untreated groups, as 
shown in Table 5. Based on accepted thresholds, sorafenib therapy appears to be cost-effective 
in both the overall cohort (ICER: $84,250) and propensity-matched cohorts (ICER: $81,249.) 
However, sorafenib is no longer cost-effective when analysis is limited to patients with 
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decompensation, with an ICER of $224,914 per life year gained in the overall decompensated 
cohort and $188,065 per life year gained in the propensity-matched decompensated cohort. 
 In a one-way sensitivity analysis of the overall cohort, we found varying the median 
survival seen with sorafenib 10% resulted in an ICER range of $72,005-$101,513 and 40% 
resulted in an ICER range from $50,142-$263,469. 
 We created two different ICER bootstrap samples—one for the overall comparison and 
one for the propensity score sample.  The median values of the distributions were higher than 
our observed statistic so the percent of times for which the ratio was less than the standard 
cutoff ($100,000) might be biased upwards.  The median ICER for the overall set was $96,327 
(95% CI: $70,253 -$193,573) and $110,982 (95% CI: $67,701-$321,127) for the propensity 
score set.  Given these ranges we cannot conclude that our realized estimates were 
significantly less than $100,000.  We found that 55% of the ICER statistics were below 
$100,000 for the overall sample (Figure 3a) and 41% for the propensity score set (Figure 3b.)  
 
DISCUSSION 
 Although sorafenib has been demonstrated to be efficacious in patients with advanced 
HCC, compensated liver disease, and good performance status, effectiveness data from real 
world clinical settings, particularly those with liver decompensation, are limited. Our study shows 
sorafenib is associated with a similar survival benefit (88 days) among elderly patients with 
advanced HCC as that seen in the SHARP trial. However, absolute median survival for both the 
treatment and control groups were shorter than observed in the SHARP trial, likely due to 
advanced patient age and higher rates of comorbid conditions, including hepatic 
decompensation.(4) Among the subgroup of patients with hepatic decompensation, the benefit 
of sorafenib was modest (31 days) and treatment is no longer cost-effective.  Notably the time 
dependent sensitivity analysis showed that sorafenib was associated with an improved survival, 
however this did not reach statistical significance. This analysis accounts for immortal time bias, 
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which is especially salient in this population, given high early mortality after diagnosis of 
advanced HCC. We did not adjust the cost analysis for immortal time bias, but sorafenib may 
not be cost effective when taking this factor into account. 
 An interim analysis of GIDEON, demonstrated sorafenib is often used in patients with 
liver dysfunction, as nearly 40% had Child Pugh class B or C disease at time of sorafenib 
initiation.(28) As expected, sorafenib was well tolerated and time-to-progression was similar (4.7 
vs 4.4 months, respectively); however, median survival was longer in Child-Pugh class A (13.6 
months [95% CI: 12.8-14.7]) than Child-Pugh class B patients (5.2 months [95% CI: 4.6-6.3].) 
(29) Notably, interpretation of GIDEON data is limited by the lack of a comparator group with 
untreated patients to assess any survival benefit. Prior studies have highlighted the importance 
of effectiveness data, as several efficacious treatments fail to show a similar benefit when used 
in clinical practice given differences in providers, treatment management, and patients.(30)  
Although there is an ongoing randomized control trial to test the efficacy and safety 
profile of sorafenib in Child-Pugh class B patients--the B Child Patient–Optimization Of 
Sorafenib Treatment (BOOST) study(31), which may better define the role for sorafenib in the 
decompensated population, these data will not be available for years. In the interim, sorafenib 
use among patients with hepatic decompensation continues to be common, accounting for over 
one-third of patients in GIDEON. Our data may serve as a guide while awaiting further data from 
BOOST.  
The cost-effectiveness of sorafenib was not previously well defined, as many prior cost-
effectiveness analyses restricted costs to medications alone, without accounting for 
comprehensive costs of the treatment strategy.(32, 33) Although non-medication costs are a 
large contributor to overall costs for many other cancers, we were surprised to find medication 
costs through Part D were the largest contributor to the difference in costs between sorafenib-
treated and control groups. This difference in relative contributions from medication costs might 
be related to patients’ short life expectancy and limited time for other health care usage. While 
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costs alone should not be used to make medical decisions, the ICERs in our analysis are 
contextualized with potential survival benefits.(18) Although sorafenib appears cost effective 
among all comers based on our base case analysis, it is of modest survival benefit and not cost 
effective in those with hepatic decompensation.  Therefore, our data suggest providers may 
consider best supportive care and earlier referral to palliative care for elderly patients with 
hepatic decompensation and advanced HCC.  
On sensitivity analysis, the ICER only varied significantly above the $100,000 threshold 
with large changes in survival benefit associated with sorafenib, but was otherwise insensitive to 
smaller changes in sorafenib associated survival benefit. The bootstrapped data show some 
uncertainty around the ICER estimation--a high proportion of the estimations in both the base-
case and propensity-score matched analysis fall outside the cost-effective range, which further 
calls into question the cost-effectiveness of sorafenib therapy. 
 Patients treated at transplant centers and/or NCI-designated centers had better 
outcomes. These associations may be driven by several factors such as higher rates of 
multidisciplinary care or better management of liver complications, which have been shown to 
improve survival(34); alternatively, this association may simply represent a referral or selection 
bias, with healthier patients who have a better prognosis being more likely to seek care at a 
tertiary care center. Further studies are needed to explore these associations; if confirmed and 
related to a difference in care delivery, this may suggest that treatment of advanced HCC 
patients be focused in expert, high-volume centers. Interestingly, being treated in an urban 
setting was consistently associated with worse survival in our study. While urban residents may 
have better access to NCI-designated or transplant centers for treatment, there is evidence that 
rural patients may have a more consistent source of healthcare and less likely to delay care.(35) 
There was no collinearity between urban setting and being seen at a transplant or NCI-
designated center, which suggests urban patients were not more likely to be seen at these 
centers. 
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 Our study has many strengths and weaknesses that warrant attention. Our data are 
limited by the use of administrative Medicare coding, which can be subject to omission or 
misclassification. Our hepatic decompensation variable relied on ICD-9 coding, so not all 
patients with decompensation in both groups were likely captured. Second, SEER-Medicare 
data has limited data for HCC tumor stage; the AJCC staging system is not widely endorsed for 
HCC due to lack of important prognostic information including Child-Pugh classification and 
performance status. It is possible that some patients in our analysis had Child-Pugh class C or 
ECOG status 3-4, resulting in BCLC stage D disease for whom sorafenib is not recommended. 
Our ECOG sensitivity analysis showed that relatively high proportions of patients in the control 
group would have to have ECOG 3-4 status to significantly impact the results of the study, even 
in scenarios with high associated hazard ratios for ECOG 3-4 status. Third, prescriptions and 
refills in Part D data are proxies for actual sorafenib use—thus we are limited in knowing if 
patients actually were taking the prescribed medications. Similarly, control patients could have 
been taking sorafenib outside the Part D program, however we attempted to account for this by 
only including patients with continuous enrollment in the Medicare program.  Fourth, it is 
possible the control group had characteristics that made them poor treatment candidates with 
worse survival; however, we attempted to account for this potential selection bias in our 
propensity score analysis for both the overall sample and the decompensated patients. An 
important consideration is that the control group was completely untreated and thus may have 
characteristics that bias them toward worse survival, so the lack of a greater survival benefit for 
the sorafenib treated group in this study is striking. Fifth, we lacked data on quality of life, which 
limited our ability to quality adjust our results for the cost-effectiveness analysis. Sorafenib has 
numerous side effects which may impact patient quality of life and should be considered when 
considering effectiveness of treatment. Finally, these data are in elderly Medicare beneficiaries, 
so the data may not be applicable to younger patients with HCC. Nonetheless this study 
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examines the real world benefit of sorafenib therapy, quantifying the impact of decompensation 
on outcomes and the cost-effectiveness of treatment. 
 In conclusion we have shown that sorafenib is associated with a survival benefit and is 
cost-effective in elderly patients with advanced HCC. However, survival benefit is diminished 
when hepatic decompensation is present, likely due to competing risk of death from underlying 
liver disease. The results are particularly salient as HCC is projected to increase in elderly age 
groups in the coming decades.(36) In addition, the results of this study are clinically relevant as 
a high proportion of patients with advanced HCC present with hepatic decompensation or 
become decompensated during the course of therapy.(29) Decompensated patients with 
advanced HCC are often treated with sorafenib in real world settings, however our data show 
that this is not a cost-effective treatment in this population due to the high costs of sorafenib and 
the marginal survival benefit associated with treatment.(29) While awaiting more granular, 
prospective ata on sorafenib effectiveness in patients with decompensated liver disease, 
careful selection of patients is warranted when considering treatment of patients with advanced 
HCC with sorafenib. 
  
Page 18 of 39
Hepatology
Hepatology















Figure 1a. Kaplan Meier survival curves of Sorafenib treated patients versus control 
 
Figure 1b. Kaplan Meier survival curves of patients with hepatic decompensation treated with 
Sorafenib versus control 
 
Figure 1c. Propensity score adjusted Kaplan Meier survival curves Sorafenib treated patients 
versus control 
 
Figure 2a. Kaplan Meier survival curves of Sorafenib treated patients stratified by presence of 
decompensation 
 
Figure 2b. Decompensated Sorafenib treated patients stratified by the number of unique hepatic 
decompensation codes (ascites, hepatic encephalopathy, and esophageal varices) in Sorafenib 
treated patients 
 
Figure 3a. Cost-effectiveness acceptability curve for sorafenib treatment in the overall sample. 
The dashed vertical line depicts the median, while the solid vertical line represents the $100,000 
threshold 
 
Figure 3b. Cost-effectiveness acceptability curve for sorafenib treatment in the propensity score 
matched sample. The dashed vertical line depicts the median, while the solid vertical line 
represents the $100,000 threshold 
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Table 1. Summary characteristic of the overall sample stratified by sorafenib treatment; 
AJCC – American Joint Committee on Cancer 
  Sorafenib Control P Value 
  N=228 N=870  
Mean Age (SD)  69.5 ± 9.4 72.9 ± 9.7 <0.001 
Gender Female (%) 60 (26.3) 228 (26.2) 1.000 
 Male (%) 168 (73.7) 642 (73.8)  
Race White (%) 164 (71.9) 655 (75.3) 0.040 
 Black (%) 22 (9.6) 109 (12.5)  
 Other (%) 42 (18.4) 106 (12.2)  
Stage Stage III (%) 120 (52.6) 463 (53.2) 0.882 
 Stage IV (%) 108 (47.4) 407 (46.8)  
Region Midwest (%) 12 (5.3) 66 (7.6) 0.400 
 Northeast (%) 24 (10.5) 112 (12.9)  
 South (%) 46 (20.2) 183 (21)  
 West (%) 146 (64) 509 (58.5)  
Urban setting 
(%) 
 158 (69.3) 597 (68.6) 0.873 
Seen at a 
teaching center 
(%) 
 129 (56.6) 416 (47.8) 0.021 





 27 (11.8) 99 (11.4) 0.816 
Seen at a  66 (28.9) 204 (23.4) 0.100 
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 0 ± 1.0 1 ± 2.0 <0.001 
 0 (%) 127 (55.7) 382 (43.9) 0.002 
 1 (%) 54 (23.7) 203 (23.3) 0.93 
 2 (%) 23 (10.1) 130 (14.9) 0.067 





 81 (35.5) 341 (39.2) 0.312 
 Hepatic encephalopathy (%) 23 (10.1) 119 (13.7) 0.183 
 Esophageal varices (%) 21 (9.2) 100 (11.5) 0.405 
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Table 2.  Multivariate Predictors of mortality in the Overall Sample and in Propensity 
Matched Sample; AJCC – American Joint Committee on Cancer; MW - Midwest 
 Overall Sample (n=1,098) Propensity Matched Sample (n=456) 
 HR 95% CI p Value HR 95% CI p value 
Sorafenib treatment 0.66 0.57-0.77 <0.001 0.55 0.46-0.67 <0.001 
AJCC Stage IV (vs. 
III) 
1.40 1.24-1.58 <0.001 1.33 1.10-1.61 0.003 
Urban setting 1.45 1.21-1.73 <0.001 1.94 1.40-2.68 <0.001 
Seen at a teaching 
center 
0.97 0.82-1.16 0.75 0.81 0.59-1.12 0.21 
Seen at a National 
Cancer Institute 
designated center 
0.77 0.62-0.97 0.024 0.77 0.54-1.11 0.16 
Seen at a transplant 
center 
0.77 0.65-0.93 <0.001 0.74 0.56-0.99 0.045 
Charlson 
Comorbidity Index 
1.00 0.96-1.04 0.88 1.01 0.93-1.09 0.85 
Age 1.01 1.00-1.01 0.14 1.01 1.00-1.02 0.038 
Presence of hepatic 
decompensation  
1.49 1.30-1.70 <0.001 1.74 1.40-2.16 <0.001 
Northeast (vs. MW) 1.08 0.80-1.46 0.60 1.38 0.83-2.29 0.22 
South (vs. MW) 0.98 0.75-1.29 0.90 0.86 0.53-1.40 0.55 
West (vs. MW) 0.98 0.75-1.28 0.88 0.93 0.60-1.46 0.76 
Male gender 1.01 0.88-1.17 0.85 1.00 0.80-1.25 0.99 
Black (vs. White) 1.20 0.98-1.48 0.086 1.21 0.77-1.91 0.40 
Other (vs. White) 1.14 0.95-1.38 0.17 0.97 0.66-1.41 0.85 
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Table 3.  Multivariate Predictors of Survival in Patients with hepatic decompensation 
(n=422); AJCC – American Joint Committee on Cancer; MW - Midwest 
 HR 95% CI p value 
Sorafenib treatment 0.61 0.47-0.79 <0.001 
AJCC Stage IV (vs. 
III) 1.27 1.04-1.56 0.0203 
Urban setting 1.57 1.14-2.16 0.0061 
Seen at a teaching 
center 0.98 0.76-1.28 0.8895 
Seen at a National 
Cancer Institute 
designated center 0.62 0.45-0.86 0.004 
Seen at a transplant 
center 0.81 0.63-1.06 0.12 
Charlson 
Comorbidity Index 0.98 0.93-1.03 0.48 
Age 1.00 0.99-1.01 0.45 
Northeast (vs. MW) 1.03 0.64-1.68 0.89 
South (vs. MW) 0.86 0.54-1.38 0.53 
West (vs. MW) 0.91 0.57-1.45 0.69 
Male 1.06 0.85-1.34 0.59 
Black (vs. White) 1.01 0.71-1.43 0.97 
Other (vs. White) 1.18 0.87-1.62 0.29 
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Table 4. Sensitivity Analysis of ECOG score- Multivariate hazard with 95% confidence 
interval with different distributions of ECOG 3-4 status in treated and control patients. 
Light gray shading indicates significant survival benefit associated with sorafenib therapy; 
ECOG - Eastern Cooperative Oncology Group 
Hazard of 
ECOG 3-4: 1.5 
Prevalence of ECOG 3-4 for Sorafenib Treated Patients 

































0 0.67 (0.57, 0.78) 0.62 (0.52, 0.73) 0.57 (0.47, 0.68) 0.53 (0.43, 0.64) 0.49 (0.39, 0.6) 0.45 (0.35, 0.56) 
0.1 0.72 (0.62, 0.83) 0.67 (0.57, 0.78) 0.62 (0.52, 0.73) 0.58 (0.48, 0.69) 0.54 (0.44, 0.65) 0.5 (0.4, 0.61) 
0.2 0.77 (0.67, 0.88) 0.72 (0.62, 0.83) 0.67 (0.57, 0.78) 0.63 (0.53, 0.74) 0.58 (0.48, 0.69) 0.54 (0.44, 0.65) 
0.3 0.81 (0.71, 0.92) 0.76 (0.66, 0.87) 0.71 (0.61, 0.82) 0.67 (0.57, 0.78) 0.63 (0.53, 0.74) 0.59 (0.49, 0.7) 
0.4 0.85 (0.75, 0.96) 0.8 (0.7, 0.91) 0.76 (0.66, 0.87) 0.71 (0.61, 0.82) 0.67 (0.57, 0.78) 0.63 (0.53, 0.74) 
0.5 0.89 (0.79, 1) 0.84 (0.74, 0.95) 0.8 (0.7, 0.91) 0.75 (0.65, 0.86) 0.71 (0.61, 0.82) 0.67 (0.57, 0.78) 
0.6 0.93 (0.83, 1.04) 0.88 (0.78, 0.99) 0.84 (0.74, 0.95) 0.79 (0.69, 0.9) 0.75 (0.65, 0.86) 0.71 (0.61, 0.82) 
0.7 0.97 (0.87, 1.08) 0.92 (0.82, 1.03) 0.87 (0.77, 0.98) 0.83 (0.73, 0.94) 0.79 (0.69, 0.9) 0.75 (0.65, 0.86) 
0.8 1.01 (0.91, 1.12) 0.96 (0.86, 1.07) 0.91 (0.81, 1.02) 0.87 (0.77, 0.98) 0.82 (0.72, 0.93) 0.78 (0.68, 0.89) 
0.9 1.04 (0.94, 1.15) 0.99 (0.89, 1.1) 0.95 (0.85, 1.06) 0.9 (0.8, 1.01) 0.86 (0.76, 0.97) 0.82 (0.72, 0.93) 
1 1.08 (0.98, 1.19) 1.03 (0.93, 1.14) 0.98 (0.88, 1.09) 0.94 (0.84, 1.05) 0.89 (0.79, 1) 0.85 (0.75, 0.96) 
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Table 5.  Cost effectiveness of sorafenib treatment in the overall sample, propensity 
score subsets, and in patients with hepatic decompensation in USD (2015); ICER – 
incremental cost-effectiveness ratio  
 Overall 


















6289 (7029) 4585 (8743) 6289 (7029) 3902 (4082) 
5387 
(5868) 


















































Mean cost 10950 31364 11678 31364 13922 32519 16557 32519 
Median survival 0.17 0.41 0.17 0.41 .17 .25 .17 .25 








Page 27 of 39
Hepatology
Hepatology










Page 28 of 39
Hepatology
Hepatology













Figure 1a. Kaplan Meier survival curves of Sorafenib treated patients versus control  
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Figure 1b. Kaplan Meier survival curves of patients with hepatic decompensation treated with Sorafenib 
versus control  
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Figure 1c. Propensity score adjusted Kaplan Meier survival curves Sorafenib treated patients versus control  
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Figure 2a. Kaplan Meier survival curves of Sorafenib treated patients stratified by presence of 
decompensation  
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Figure 2b. Decompensated Sorafenib treated patients stratified by the number of unique hepatic 
decompensation codes (ascites, hepatic encephalopathy, and esophageal varices) in Sorafenib treated 
patients  
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Figure 3a. Cost-effectiveness acceptability curve for sorafenib treatment in the overall sample. The dashed 
vertical line depicts the median, while the solid vertical line represents the $100,000 threshold  
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Figure 3b. Cost-effectiveness acceptability curve for sorafenib treatment in the propensity score matched 
sample. The dashed vertical line depicts the median, while the solid vertical line represents the $100,000 
threshold  
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Supplemental Table 1.  Multivariate Predictors of Survival in Propensity Matched 
Decompensated Patients (n=162); AJCC – American Joint Committee on Cancer; MW - 
Midwest 
 HR 95% CI p value 
Sorafenib 0.62 0.45-0.87 0.006 
AJCC Stage IV (vs. 
III) 1.48 1.05-2.08 0.027 
Urban setting 1.42 0.82-2.47 0.21 
Seen at a teaching 
center 1.53 0.97-2.41 0.067 
Seen at a National 
Cancer Institute 
designated center 0.75 0.46-1.23 0.25 
Seen at a 
transplant center 0.59 0.38-0.92 0.019 
Charlson 
Comorbidity Index 0.94 0.83-1.08 0.38 
Age 1.00 0.98-1.01 0.54 
Northeast (vs. MW) 1.46 0.57-3.77 0.43 
South (vs. MW) 1.55 0.63-3.81 0.34 
West (vs. MW) 1.83 0.77-4.36 0.17 
Male gender 1.01 0.71-1.45 0.95 
Black (vs. White) 0.93 0.51-1.69 0.80 
Other (vs. White) 1.27 0.75-2.17 0.38 
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Supplemental Table 2.  Multivariate Predictors of Survival in Sorafenib Treated Patient 
(n=228); AJCC – American Joint Committee on Cancer; MW - Midwest 
 HR 95% CI p value 
 AJCC Stage IV (vs. 
III) 1.23 0.93-1.62 0.15 
Urban setting 2.12 1.32-3.41 0.002 
Seen at a teaching 
center 0.72 0.46-1.14 0.16 
Seen at a National 
Cancer Institute 
designated center 0.91 0.53-1.54 0.72 
Seen at a transplant 
center 0.88 0.58-1.33 0.54 
Charlson 
Comorbidity Index 1.03 0.92-1.16 0.59 
Age 0.99 0.98-1.01 0.35 
Presence of hepatic 
decompensation  1.29 0.94-1.76 0.11 
Northeast (vs. MW) 1.59 0.75-3.33 0.22 
South (vs. MW) 1.09 0.54-2.19 0.81 
West (vs. MW) 1.14 0.59-2.20 0.69 
Male gender 1.15 0.83-1.61 0.40 
Black (vs. White) 1.13 0.69-1.85 0.64 
Other (vs. White) 1.15 0.77-1.70 0.50 
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Supplemental Table 3. Sensitivity Analysis of ECOG score- Multivariate hazard with 95% 
confidence interval with different distributions of ECOG 3-4 status in treated and control 
patients. Light gray shading indicates significant survival benefit associated with sorafenib 




ECOG 3-4: 2.0 
Prevalence of ECOG 3-4 for Sorafenib Treated Patients 























0 0.67 (0.57, 0.78) 0.57 (0.47, 0.68) 0.49 (0.39, 0.6) 0.41 (0.31, 0.52) 0.33 (0.23, 0.44) 0.26 (0.16, 0.37) 
0.1 0.77 (0.67, 0.88) 0.67 (0.57, 0.78) 0.58 (0.48, 0.69) 0.5 (0.4, 0.61) 0.43 (0.33, 0.54) 0.36 (0.26, 0.47) 
0.2 0.85 (0.75, 0.96) 0.76 (0.66, 0.87) 0.67 (0.57, 0.78) 0.59 (0.49, 0.7) 0.52 (0.42, 0.63) 0.45 (0.35, 0.56) 
0.3 0.93 (0.83, 1.04) 0.84 (0.74, 0.95) 0.75 (0.65, 0.86) 0.67 (0.57, 0.78) 0.6 (0.5, 0.71) 0.53 (0.43, 0.64) 
0.4 1.01 (0.91, 1.12) 0.91 (0.81, 1.02) 0.82 (0.72, 0.93) 0.74 (0.64, 0.85) 0.67 (0.57, 0.78) 0.6 (0.5, 0.71) 
0.5 1.08 (0.98, 1.19) 0.98 (0.88, 1.09) 0.89 (0.79, 1) 0.81 (0.71, 0.92) 0.74 (0.64, 0.85) 0.67 (0.57, 0.78) 
0.6 1.14 (1.04, 1.25) 1.04 (0.94, 1.15) 0.96 (0.86, 1.07) 0.88 (0.78, 0.99) 0.8 (0.7, 0.91) 0.73 (0.63, 0.84) 
0.7 1.2 (1.1, 1.31) 1.11 (1.01, 1.22) 1.02 (0.92, 1.13) 0.94 (0.84, 1.05) 0.86 (0.76, 0.97) 0.8 (0.7, 0.91) 
0.8 1.26 (1.16, 1.37) 1.16 (1.06, 1.27) 1.08 (0.98, 1.19) 1 (0.9, 1.11) 0.92 (0.82, 1.03) 0.85 (0.75, 0.96) 
0.9 1.31 (1.21, 1.42) 1.22 (1.12, 1.33) 1.13 (1.03, 1.24) 1.05 (0.95, 1.16) 0.98 (0.88, 1.09) 0.91 (0.81, 1.02) 
1 1.36 (1.26, 1.47) 1.27 (1.17, 1.38) 1.18 (1.08, 1.29) 1.1 (1.0, 1.21) 1.03 (0.93, 1.14) 0.96 (0.86, 1.07) 
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